{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McEvoy CT"],"funding":["National Center for Advancing Translational Sciences","Office of Dietary Supplements","NCATS NIH HHS","Oregon Clinical and Translational Research Institute","NHLBI NIH HHS","National Heart, Lung, and Blood Institute","National Institutes of Health","NIH HHS"],"pagination":["66-77"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5696784"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["58"],"pubmed_abstract":["Despite strong anti-smoking efforts, at least 12% of American women cannot quit smoking when pregnant resulting in >450,000 smoke-exposed infants born yearly. Smoking during pregnancy is the largest preventable cause of childhood respiratory illness including wheezing and asthma. Recent studies have shown a protective effect of vitamin C supplementation on the lung function of offspring exposed to in utero smoke in a non-human primate model and an initial human trial. Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) is a randomized, double-blind, placebo-controlled trial to evaluate pulmonary function at 3months of age in infants delivered to pregnant smokers randomized to 500mg/day of vitamin C versus placebo during pregnancy. Secondary aims evalua"],"journal":["Contemporary clinical trials"],"pubmed_title":["Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP): Rationale, design, and methods of a randomized, controlled trial of vitamin C supplementation in pregnancy for the primary prevention of effects of in utero tobacco smoke exposure on infant lung function and respiratory health."],"pmcid":["PMC5696784"],"funding_grant_id":["R01 HL105460","UL1TR000128","UL1 TR000128","UL1 TR002369","P51 OD011092","R01 HL105447"],"pubmed_authors":["Mitchell J","Peters D","Metz J","Tepper RS","McEvoy CT","Schilling DG","Spindel ER","Schuff R","Haas D","Vuylsteke B","Shorey-Kendrick LE","Scherman AJ","Morris CD","Milner KF","Tiller CJ","Jackson K"],"additional_accession":[]},"is_claimable":false,"name":"Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP): Rationale, design, and methods of a randomized, controlled trial of vitamin C supplementation in pregnancy for the primary prevention of effects of in utero tobacco smoke exposure on infant lung function and respiratory health.","description":"Despite strong anti-smoking efforts, at least 12% of American women cannot quit smoking when pregnant resulting in >450,000 smoke-exposed infants born yearly. Smoking during pregnancy is the largest preventable cause of childhood respiratory illness including wheezing and asthma. Recent studies have shown a protective effect of vitamin C supplementation on the lung function of offspring exposed to in utero smoke in a non-human primate model and an initial human trial. Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) is a randomized, double-blind, placebo-controlled trial to evaluate pulmonary function at 3months of age in infants delivered to pregnant smokers randomized to 500mg/day of vitamin C versus placebo during pregnancy. Secondary aims evalua","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2025-04-04T14:10:00.156Z","creation":"2019-03-26T23:44:08Z"},"accession":"S-EPMC5696784","cross_references":{"pubmed":["28495620"],"doi":["10.1016/j.cct.2017.05.008"]}}